ReviewNPJ breast cancer2016
Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants.
Review in NPJ breast cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 104 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
104 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial.Nature medicine · 2025Trial
- A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer.Breast cancer research : BCR · 2018Trial
- Integrative Molecular Profiling of miR-548f-3p in Triple-Negative Breast Cancer HighlightsInternational journal of molecular sciences · 2026Article
- Overcoming Drug Resistance by Paclitaxel Resistance in Triple-Negative Breast Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Review
- Low-dose DOX-polygodial nanosystem modulates the CD47/CALR axis for safer triple negative breast cancer treatment.Nanoscale advances · 2026Article
- Unravelling Tinengotinib's Mechanistic Landscape in Triple-Negative Breast Cancer Via Network Pharmacology and in Silico Simulation Techniques.Cell biochemistry and biophysics · 2026Article
- The Algal Antioxidant Carotenoid Diatoxanthin as a Modulator of Inflammation and Angiogenesis in Triple-Negative Breast Cancer Cells.Antioxidants (Basel, Switzerland) · 2026Article
- Therapeutic assessment ofFrontiers in oncology · 2026Article
- Whole-exome sequencing for identification of specific gene mutations in an Indian cohort of triple-negative breast cancer patients.Discover oncology · 2025Article
- Comparative Genomic and Microenvironmental Profiles of Hereditary and Sporadic TNBC in Colombian Women.Biology · 2025Article
- Seven Shades of Triple Negativity: A Review Unveiling the Low-Grade Spectrum of Breast Cancer.Cancers · 2025Review
- Multi-receptor targeted therapy of breast cancer and brain metastases with a novel QUAD-drug conjugate.Breast cancer research : BCR · 2025Article
- Prognostic Potential of Apoptosis-Related Biomarker Expression in Triple-Negative Breast Cancers.International journal of molecular sciences · 2025Article
- Breast carcinomas associated with microglandular adenosis are linked to germline alterations in homologous recombination-deficiency genes.NPJ breast cancer · 2025Article
- Natural history and prognostic nomogram of untreated triple negative breast cancer based on SEER database.Scientific reports · 2025Article
- PML localization in tumor associated macrophages as a prognostic marker in triple negative breast cancer.Scientific reports · 2025Article
- Mitochondria-Targeted Titanium Complex Exerts Potent Anticancer Activity by Disturbing Iron Homeostasis.ACS pharmacology & translational science · 2025Article
- Liposomal oncolytic adenovirus as a neoadjuvant therapy for triple-negative breast cancer.Scientific reports · 2025Article
44 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triple-negative breast cancers (TNBCs), defined by lack of expression of estrogen receptor, progesterone receptor and HER2, account for 12-17% of breast cancers and are clinically perceived as a discrete breast cancer subgroup. Nonetheless, TNBC has been shown to constitute a vastly heterogeneous disease encompassing a wide spectrum of entities with marked genetic, transcriptional, histological and clinical differences. Although most TNBCs are high-grade tumors, there are well-characterized low-grade TNBCs that have an indolent clinical course, whose natural history, molecular features and optimal therapy vastly differ from those of high-grade TNBCs. Secretory and adenoid cystic carcinomas are two histologic types of TNBCs underpinned by specific fusion genes; these tumors have an indolent clinical behavior and lack all of the cardinal molecular features of high-grade triple-negative disease. Recent studies of rare entities, including lesions once believed to constitute mere benign breast disease (e.g., microglandular adenosis), have resulted in the identification of potential precursors of TNBC and suggested the existence of a family of low-grade triple-negative lesions that, despite having low-grade morphology and indolent clinical behavior, have been shown to harbor the complex genomic landscape of common forms of TNBC, and may progress to high-grade disease. In this review, we describe the heterogeneity of TNBC and focus on the histologic and molecular features of low-grade forms of TNBC. Germane to addressing the challenges posed by the so-called triple-negative disease is the realization that TNBC is merely a descriptive term, and that low-grade types of TNBC may be driven by distinct sets of genetic alterations.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.